Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03938337 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03938337 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants.
The verdict
NCT03938337, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
To assess the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and neck.
Interventions
- DRUG Cohort 1 Not Previously Treated
- DRUG Cohort 2 Treated Previously
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-10-08 |
| Est. Completion | 2020-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03938337
The ClinicalTrials.gov registry entry for NCT03938337 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cohort 1 Not Previously Treated is the first listed.
NCT03938337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03938337 about?
NCT03938337 is a clinical study titled "Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer". To assess the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and neck.
What is the current status of trial NCT03938337?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-10-08. Estimated completion is 2020-04-03.
What interventions are being tested in trial NCT03938337?
The interventions under investigation include: Cohort 1 Not Previously Treated (DRUG), Cohort 2 Treated Previously (DRUG).
Who is sponsoring clinical trial NCT03938337?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.